A real world experience of empagliflozin in patients with type 2 diabetes: in a medical center in southern of taiwan

  • At: 2017 FIP Congress in Seoul (South Korea)
  • Type: Poster
  • By: CHEN, Jungfang (Chi Mei medical center, Department of Pharmacy, Tainan City, China Taiwan)
  • Co-author(s): Jungfang Chen
  • Abstract:


    We collected adult participants in our outpatient department with a HbA1C of 7 or higher; with type 2 diabetes mellitus; and who received empagliflozin at clinically relevant doses for at least 24 weeks. We assessed the effect of weight loss and assessed markers of glycaemic control: glycated haemoglobin (percentage of HbA1c).



  • The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress. Please login